Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Abbott (ABT) Stock Moves -1.91%: What You Should Know

Published 03/05/2020, 05:50 AM
Updated 07/09/2023, 06:31 AM

In the latest trading session, Abbott (ABT) closed at $80.52, marking a -1.91% move from the previous day. This move was narrower than the S&P 500's daily loss of 3.39%. Elsewhere, the Dow lost 3.58%, while the tech-heavy Nasdaq lost 3.1%.

Prior to today's trading, shares of the maker of infant formula, medical devices and drugs had lost 8.34% over the past month. This has lagged the Medical sector's loss of 1.65% and the S&P 500's loss of 4.8% in that time.

ABT will be looking to display strength as it nears its next earnings release. On that day, ABT is projected to report earnings of $0.70 per share, which would represent year-over-year growth of 11.11%. Our most recent consensus estimate is calling for quarterly revenue of $7.98 billion, up 5.86% from the year-ago period.

For the full year, our Zacks Consensus Estimates are projecting earnings of $3.60 per share and revenue of $33.67 billion, which would represent changes of +11.11% and +5.54%, respectively, from the prior year.

Investors might also notice recent changes to analyst estimates for ABT. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.

Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. ABT is currently sporting a Zacks Rank of #3 (Hold).

Digging into valuation, ABT currently has a Forward P/E ratio of 22.82. For comparison, its industry has an average Forward P/E of 25.62, which means ABT is trading at a discount to the group.

Also, we should mention that ABT has a PEG ratio of 2.16. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. ABT's industry had an average PEG ratio of 2.82 as of yesterday's close.

The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 51, putting it in the top 20% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.



Abbott Laboratories (NYSE:ABT

Original post

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.